|
Rigel Assumes Development Responsibility For Inhaled Asthma Therapy
Medical News Today (press release) Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced that the company will assume development of R343, its inhaled syk inhibitor for allergic asthma that recently completed several Phase 1 clinical trials. Pfizer Inc. is returning full rights to the … |
View full post on asthma – Google News